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Abstract: Antimicrobial peptides constitute a diverse class of naturally occurring 
antimicrobial molecules which have activity against a wide range of pathogenic 
microorganisms. Antimicrobial peptides are exciting leads in the development of novel 
biocidal agents at a time when classical antibiotics are under intense pressure from 
emerging resistance, and the global industry in antibiotic research and development 
stagnates. This review will examine the potential of antimicrobial peptides, both natural 
and synthetic, as novel biocidal agents in the battle against multi-drug resistant  
pathogen infections.  
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1. Introduction 
1.1. Antimicrobial Peptides 
Despite continuing efforts, the increasing prevalence of resistance among pathogenic bacteria to 
common antibiotics has become one of the most significant concerns in modern medicine. With 
significantly reduced investment in antimicrobials research and development among major 
pharmaceutical companies, novel alternatives to existing treatment strategies are not being produced at 
a sufficient rate to keep pace with the emergence of resistance and the supply pipeline runs perilously 
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close to drying up [1]. Incidences of hospital-acquired and community-acquired antibiotic resistant 
Staphylococcus aureus infections have risen dramatically in recent years [2], with almost 50% of 
hospital acquired Staphylococcus aureus infections classified as methicillin resistant and 30% of 
enterococci exhibiting vancomycin resistance [3]. In 2010, the Infectious Diseases Society of America 
launched its 10 × 20 initiative, calling for a global commitment to new antibacterial drug development, 
with the goal of ten new antibiotic agents by the year 2020 [4]. In addition, continued extensive use of 
the limited classes of effective antibiotics currently available threatens to call time on the ‘antibiotic 
era’. In the past decade, the crisis of antimicrobial resistance has worsened significantly and there 
exists an urgent requirement for new antimicrobial agents with activity against multidrug resistant 
pathogens [5].  
One area of antimicrobial drug research that does shows significant promise is in the discovery and 
development of antimicrobial peptides (AMPs). Antimicrobial peptides in nature serve as important 
defensive weapons throughout the animal and plant kingdoms against a broad spectrum of bacterial 
and fungal pathogens [6]. Sources range from single celled microorganisms, such as bacteria 
themselves (bacteriocins) [7], to invertebrates [8]. As well as having a direct effect on the 
microorganism, antimicrobial peptides have been proven to promote the accumulation of immune cells 
including macrophages, neutrophils and lymphocytes [9]; neutralize lipopolysaccharide endotoxin 
derived from Gram-negative bacteria [10]; aid wound repair; stimulate angiogenesis [11] and control 
the actions of the innate and adaptive immune response with little or no resistance development 
reported. Antimicrobial peptides exert their microbicidal effect via disruption of the microbial cell 
membrane together with intracellular action [12,13].  
Antimicrobial peptides are short (typically ranging from 12–100 amino acid residues in length), 
exhibit rapid and efficient antimicrobial toxicity against a range of pathogens [14,15] and constitute 
critical effector molecules in the innate immune system of both prokaryotic and eukaryotic  
organisms [16]. To date, over 1700 endogenous antimicrobial peptides have been isolated with many 
more synthetic analogues reported in the literature [17]. Structure activity relationship analyses have 
yielded vital information relating to the structural features of effective antimicrobial peptides, 
indicating that antimicrobial activity is governed primarily by charge and hydrophobicity [18], and that 
the initial target is the negatively charged bacterial cell membrane [19]. These studies have also 
facilitated the design of ultrashort, highly active antimicrobial peptide scaffolds [20,21] which may be 
prepared via established facile, solid phase synthetic protocols at lower costs compared with their 
natural antimicrobial peptide counterparts [22,23].  
1.2. Cationic Antimicrobial Peptides 
The majority of antimicrobial peptides are cationic with more than a thousand characterized and are 
thus termed cationic antimicrobial peptides (CAPs) [24]. Naturally derived cationic antimicrobial 
peptides typically consist of a net positive charge between +2 and +9, due to the presence of few or no 
acidic residues, such as glutamate or aspartate and a high number of cationic amino acids such as 
lysine or arginine and/or histidine [25]. Hydrophobic residues, including tryptophan and branched 
amino acids such as valine, form 30–50% of the total peptide structure and serve a vital role in 
allowing a typical amphiphilic structure to form upon interaction with membranes [26]. This 
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characteristic together with the presence of dense areas of high positive charge allow cationic 
antimicrobial peptides to exert their antimicrobial effect. Alteration of this net charge to hydrophobic 
ratio can vary the activity and spectrum of the peptide against a host of microorganisms. The increase 
in activity that can be therapeutically achieved by tapering the lipophilic:charge ratio is provided by 
the example of glycopeptides. Glycopeptides, for example vancomycin, represent one of the last line of 
effective antibiotics against Methicillin resistant Staphylococcus aureus. Lipoglycopeptide derivatives 
of vancomycin in development include oritavancin and dalbavancin which possess increased activity 
against vancomycin-resistant strains [27]. Slight modifications in the balance of hydrophobicity and 
charge can give rise to marked changes in antimicrobial selectivity/activity [28]. Cationic antimicrobial 
peptides, as a class of compounds, have broad structural diversity and antimicrobial spectrum influenced 
primarily by the amino acids that constitute the primary sequence of the peptide [29]. 
Although the secondary structures that antimicrobial peptides adopt may vary between classes they 
share the same characteristic of developing an amphipathic structure and being cationic under 
physiological conditions [30,31]. Secondary structures include amphiphilic β-sheet structures containing 
two or three stabilizing disulphide bonds, often with a short α-helical segment and/or two to four  
β-strands. These disulphide bridges form as a result of a cysteine-rich primary sequence. Examples of 
these peptides in nature include several classes of mammalian host defense peptides including  
α-defensin and β-defensin [32]. Linear peptides are unordered in hydrophilic solutions but form 
amphipathic α-helices upon contact with cell membranes and in a hydrophobic environment [33].  
These peptides are of particular interest as one face of the helix structure contains a majority of 
hydrophobic residues whereas the opposite face contains mainly polar amino acids allowing efficient 
solubilization of microbial membranes [26]. Amphipathic α-helices lack cysteine and are thus unable 
to form disulphide bridges [34]. Examples in nature include mellitin derived from honeybee  
venom [35], magainin obtained from the skin secretions of the frog species Xenopus laevis [36] and the 
cecropins, a group of the dipteran insect defense peptides [37]. Cyclic peptides are a less prevalent 
structural class of cationic antimicrobial peptides that contain β-turn influenced by a single disulphide 
bond and include a dodecapeptide from bovine neutrophils [38].  
Extended structures with a high regularity of one or two amino acid residues, such as proline, 
glycine, histidine or tryptophan, make up the remainder of the four major structural varieties [15,39]. 
Extended cationic peptides have no defined or typical structure due to the existence of novel folds. 
Examples in nature include the porcine derived tritrpticin [40] and the bovine neutrophil peptide 
indolicidin [41]. Indolicidin is a linear antimicrobial peptide consisting of a 13 amino acid structure 
high in tryptophan residues (~40%) [42]. Both these peptides form boat-like structures in the presence 
of cell membranes as the high tryptophan content interacts with the hydrophobic layer of the 
membrane with the remaining cationic arginine and lysine residues orientated towards the aqueous 
environment [43]. The cationic AMP mimetic tyrocidin was the first commercially available antibiotic. 
However major issues with toxicity toward human blood and reproductive cells lead to its withdrawal 
from the market [44]. The polypeptide bacitracin has had a more successful introduction clinically 
incorporated with both neomycin and polymyxin B in the topical product Neosporin® licensed for the 
topical treatment of a variety of localized skin and eye infections [45].  
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1.3. Anionic Antimicrobial Peptides 
Despite the vast majority of antimicrobial peptides being cationic in nature, a significant number of 
anionic AMPs have been reported; serving as important weapons in the eukaryotic innate immune 
response [46–48]. Peptides that are anionic in nature tend to be rich in glutamic and aspartic acids and 
include the amphibian peptide Maximin-H5 and Dermcidin, a peptide derived from human  
sweat [49,50]. Anionic antimicrobial peptides commonly consist of 5 to 70 amino acid residues, 
possessing a net charge of −1 or −2 although structural characterization demonstrated that the 
truncated form of bovine peptide B, termed enkelytin, can possess a net charge as high as −7 [48,51]. 
Although less common, anionic peptides of 300 residues in length and net charge −20 have been  
reported [52–54]. Similarly to their cationic counterparts, anionic antimicrobial peptides can adopt 
varying amphiphilic structures such as the α-helix and the β-sheet conformations with interaction with 
the microbial membrane key to activity.  
A disadvantage of many anionic antimicrobial peptides is that they often require cations, for 
example zinc (Zn2+), as cofactors for biocidal activity [55]. This may be why they are generally located 
at epithelia; sites were both ionic secretion and microbial susceptibility are highest. Anionic peptides, 
for example surfactant-associated anionic peptides present in pulmonary tissue, have been shown to 
possess increased potency against both Gram-positive and Gram-negative bacteria in the presence of 
synergistic cationic antimicrobial peptides and Zn2+ [56,57]. These cationic moieties act as a cationic 
linkage between the anionic antimicrobial peptide and the anionic microbial cell membrane. This allows 
transport of the anionic peptide to intracellular targets without damaging to the structure of the 
microbial membrane [55,58]. Anionic peptides target ribosomes within the cell inhibiting ribonulease 
activity, thus resulting in microbial cell death [59,60].  
1.4. Amphibian Antimicrobial Peptides 
Amphibian derived peptides are excellent examples of naturally occurring, structurally diverse 
peptides with high antimicrobial potency. These compounds are released in skin secretions often at 
high concentrations and their production reflects the evolution of amphibians to their humid habitat, an 
environment also suitable for the growth and proliferation of opportunistic pathogenic bacteria and 
fungi [61]. Such peptides are also beginning to show promise against cancer, as anti-tumor  
compounds [62] and also possess anti-viral activity, with potential benefits against HIV [63]. They 
also show activity against eukaryotic cells and therefore provide a means by which amphibians may be 
protected from predation [64]. The potential therefore exists that amphibian derived antimicrobial 
peptides may also be cytotoxic to humans. Such peptides are released naturally in response to injury or 
stress via contraction of myocytes surrounding the glands [65] and this may be replicated in the 
laboratory through the use of mild electrical stimulation [66] or injecting norepinephrine into the 
dorsal sac [67].  
Structural characterization has facilitated their synthetic production via solid phase peptide 
synthesis (SPPS). In frogs, variations in the sequence and spectrum of activity of these peptides are 
considerable with hundreds of characterized peptides providing protection against a vast range of 
bacterial and fungal species [61,68,69]. The majority of antimicrobial peptides from frogs are cationic 
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due to a high presence of lysine, with at least 50% of amino acids being hydrophobic of which leucine 
is most prevalent and an amphipathic α-helix secondary structure predominates at the cell membrane  
interface [61,70]. Relevant genera of frog studied include Bombina [71], Xenopus [36], Rana [72], 
Phyllomedusa [73] and Litoria [74]. The species Bombina maxima, commonly known as the Chinese 
red belly toad has as many as forty genes linked to the production of different antimicrobial  
peptides [75]. Research conducted by Lai et al. showed that Bombina maxima produced a group of 
peptides called maximins that demonstrated minimum inhibitory concentration (MIC) values in the 
µg/mL range against a broad spectrum of microbial and fungal pathogens including Staphylococcus 
aureus, Escherichia coli, Bacillus dysenteriae, Klebsiella pneumoniae and Candida albicans [76]. 
Both maximin-3 and maximin-4 were the most potent peptides tested with maximin-4 having the 
lowest MIC value of 2.7 µg/mL against Staphylococcus aureus. Maximin-4 consists of twenty seven 
amino acids and has the potential to be produced synthetically via SPPS. Dermaseptins are a family of 
linear lysine-rich cationic antimicrobial peptides derived from the genus Phyllomedusa. They consist 
of between twenty eight and thirty four amino acid residues and have been shown to inhibit the growth 
of a wide variety of Gram-positive and Gram-negative bacteria, fungi, protozoa and yeast [73,77].  
1.5. Rational Design and Selection of an Antimicrobial Peptide Motif 
The diverse range of antimicrobial peptides available in nature provides a vast scope for the design 
of novel and improved synthetic variations. Structure and its effect on the hydrophobic:charge ratio is 
more important with regard to antimicrobial activity than size and the manipulation of primary amino 
acid sequence can improve factors such as specificity, toxicity and stability [12,78]. Ultrashort 
antimicrobial peptides consist of approximately four or five amino acids residues, with amino acid 
selection fulfilling the minimum range of functionalities required for effective antimicrobial activity. 
These functionalities include a charged moiety such as arginine and a lipophilic unit, most commonly 
tryptophan, forming an antimicrobial pharmacophore with the correct balance between charge and 
lipophilicity [79].  
Strom et al. have proven that tryptophan provides better bulk and lipophilicity than tyrosine and a 
minimum of two bulk and two charged residues are required to be present to give activity against 
staphylococci, with Escherichia coli requiring an additional bulk tryptophan. Arginine also acts a 
better source of charge than lysine within the minimum motif [78]. However arginine is difficult to 
work with in terms of SPPS [80,81]. The obvious advantage to the use of ultrashort antimicrobial 
peptide is the large reduction in cost in synthesizing these molecules relative to synthetic variants of 
naturally occurring antimicrobial peptides. The attachment of an acyl chain to an active or inert 
ultrashort cationic peptide also potentially leads to an increased action against microorganisms in a 
similar way to native cationic antimicrobials [82]. Small alterations of the total methylene units present 
can also modify the spectrum of activity for the antimicrobial, the cell specificity and therefore levels 
of hemolysis [83]. Previous studies by Makovitski et al. reported however that peptides containing 
four amino acids would find it difficult to form a characterized, stable amphipathic structure, therefore 
questions still relate to their mode of action. Reported results also show that the balance of hydrophobicity 
and charge play an important role just as in the larger antimicrobial peptides. By altering both, the 
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amino acid residues and the acyl chain length, it was found that increasing hydrophobicity and/or 
charge is not necessarily indicative to increasing antimicrobial function [84].  
Host and microbial proteases and the unfavorable pharmacokinetics they bring present a major 
barrier to the use of peptides as antimicrobials in vivo, with many peptides limited to use as topical 
applications. Human chymotrypsin-like enzymes function at basic amino acid residues [85], therefore 
antimicrobial peptides are a viable target due to the requirement of basic residues to be present for 
antimicrobial activity. Simple α-helical or linear structures in particular are susceptible to proteolysis 
by a range of microbial proteases [86]. As proteases will only recognize natural L-amino acid residues, 
a switch to the use of D-amino acids at susceptible points will render the peptide partially or totally 
resistant to proteolysis without loss of antimicrobial activity [87]. L-stereoisomers also tend to be more 
hemolytic than their D counterparts [88]. Antimicrobial peptides are expensive to synthesize and costs 
are increased further by the use of D-enantiomers thus a more viable alternative is to select unnatural 
amino acids, such as ornithine. The use of ornithine as a charged moiety is preferable as the use of a 
non-coded amino acid provides stability against proteases [78]. Examples of synthetic harnessing of 
ornithine’s properties are demonstrated by Bisht et al. They demonstrated the potent action of 
ultrashort tetrapeptides with two ornithines representing the charged portion and two tryptophans 
providing bulk and hydrophobicity [21]. Modification occurred with conjugation of cinnamic groups to 
the Nα-amino terminus of ornithine. The incorporation of ornithine into the lipopeptide scaffold has 
also been tested in the synthetic peptide MSI-843 [89]. Containing six ornithine residues out of a total 
ten and a conjugated octanyl terminus, excellent activity was shown against Gram-positive 
Staphylococcus aureus; Gram-negative Pseudomonas aeruginosa and Escherichia coli and the fungus 
Candida albicans.  
1.6. Ultrashort Cationic Antimicrobial Peptides 
Ultrashort cationic antimicrobial peptides consist of approximately four or five amino acids 
residues, with amino acid selection fulfilling the minimum range of properties required for effective 
antimicrobial activity to take place. The use of ultrashort cationic antimicrobial peptides is 
advantageous in terms of manufacture with reduced production costs and synthesis times.  
Their production correlates to a trend amongst peptide companies that has seen an increase in the 
production of these smaller peptides in relation to larger, more expensive natural peptides [90,91]. 
Haug and colleagues discovered, using lactoferrin derivatives, that a minimum motif existed for 
antibacterial action against many forms of bacteria including strains of Staphylococcus aureus resistant 
to common antibiotic regimens [79,92–97]. Of high importance to their activity is the overall balance 
between lipophilicity and charge with the presence of two units of bulk and two cationic charges 
mandatory for membrane interaction and antimicrobial activity [16,78]. Naturally occurring 
antimicrobial peptides have a largely lipophilic character with the primary sequence consisting of  
30–50% bulky hydrophobic residues such as tryptophan [26]. Tetra and pentapeptides possess a 
relatively small pharmacophore with limited bulk, thus in order to produce a favorable increase in the 
lipophilicity to charge ratio the amino terminus is acylated with a variety of hydrocarbon moieties [98]. 
With this knowledge Haug et al. produced a series of smaller dipeptides of a general formula XRY 
where; X represented a variant of a bulky amino acid with a lipophilic side chain, for example 
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cyclohexylalanine; R represented arginine, the charged moiety; Y represented a C-terminal ester or a 
lipophilic amide derivative [79]. Both X and Y provided bulk to the short pharmacophore.  
A 2,5,7-tri-tert-butyl-tryptophan-arginine-benzyl amide was shown to be the most active peptide in the 
study. This structure correlates with the minimum requirement for two units of bulk, provided by the 
tryptophan derivative and benzene ring of the benzyl amide and two units of charge imparted by 
arginine’s guanidino group and the free Nα-amino terminus. Central to this theory Bisht et al. produced 
a series of ornithine and tryptophan containing tetrapeptides and evaluated them against planktonic 
forms of various Gram-positive and Gram-negative bacteria [21]. To increase hydrophobicity cinnamic 
acid and its derivatives were attached to the amino terminus of the peptide motif. These terminal 
carboxylic acids included cinnamic acid, 3,4-dimethoxycinnamic acid, 4-hydroxy cinnamic acid and  
3-(4-hydroxyphenyl) propionic acid. 
1.7. Lipopeptides 
Lipopeptides are essentially a peptide attached to a lipid moiety. Such a peptide may include an 
antimicrobial peptide. Native lipopeptides are formed in bacteria and fungi non-ribosomally by 
cultivation on a range of carbon sources to form complex cyclic structures [99]. They normally consist 
of a sequence of six or seven amino acids with a N-terminal fatty acid moiety attached. They are active 
against a range of multi-resistant bacteria and fungi [100]. Antimicrobial lipopeptides are primarily 
bacterial compounds synthesized via non-ribosomal biosynthetic pathways and comprise a peptidyl 
portion conjugated to a fatty acid to form an acylated peptide [99]. Many naturally occurring 
lipopeptides are cyclized and may also contain unnatural amino acids that confer stability against 
proteolytic degradation. Lipopeptides may comprise an anionic (e.g., Daptomycin, surfactin) or 
cationic (e.g., polymyxin B, colistin) peptide motif, which dictates the spectrum of activity [99]. Fatty 
acids, fatty amines, alcohols and gylceryl esters have all been shown to exhibit varying degrees of 
antimicrobial activity [101,102], whilst acylation of peptide scaffolds has been demonstrated to 
significantly improve antimicrobial activity [99,103]. For example when the natural occurring 
polymyxin is coupled to a fatty acid tail, removal of this tail leads to a decrease in antimicrobial  
action [104]. The conjugation of a fatty acid moiety at the N-terminus can also compensate for a loss 
of hydrophobicity within the peptidic chain based on amino acid residue selection [105]. Therefore, the 
combination of an optimized peptidyl scaffold and N-terminal acyl substituent (i.e., fatty acid) with 
inherent antimicrobial activities represents an approach to the development potent antimicrobial 
agents, whereby spectrum of activity may be modulated via modification of the N-terminal substituent, 
whilst circumventing the commercial barriers associated with the manufacture of natural antimicrobial 
peptides in high yields.  
1.8. Licensed and Commercially Available Lipopeptides 
A variety of anionic and cationic lipopeptides are currently licensed for commercial use, thus 
highlighting the clinical potential of these antimicrobials. These include daptomycin, polymyxin B and 
polymyxin E (colistin).  
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1.8.1. Daptomycin 
Daptomycin is an anionic lipopeptide that is produced naturally by Streptomyces roseosporus 
(Actinobacteria). Daptomycin is a cyclic depsipeptide consisting of thirteen amino acids, which 
includes three D-amino acid residues (D-asparagine, D-alanine, and D-serine) linked to a hydrocarbon 
tail ten carbons in length derived from decanoic acid (Figure 1). Synthetic production of lipopeptides 
has led to the approval of the lipopeptide daptomycin which gained US and EU product licenses in 
2003 and 2006 respectively for skin and soft tissue infections [106]. More recently it has been passed 
for use in the US for staphylococcal bacteremia and right sided endocarditis [107]. Daptomycin is also 
available in the UK as an injection and is commercially available as the brand Cubicin® with further 
research showing possible use in the treatment of enterococcal bacteremia caused by Enterococcus 
faecium and Enterococcus faecalis [108]. Daptomycin, itself anionic, is dependent on the presence of 
calcium cations for antimicrobial activity. Electrostatic interactions allow daptomycin to alter to an 
active conformation. Increased amphiphilicity and integration of daptomycin into bacterial membranes 
occurs via the acyl chains [109–113]. This results in the formation of micelle-like structures with the 
lipid tails of daptomycin pointing inwards and the anionic side groups held together by calcium  
ions [114]. At bacterial membranes these micelles dissociate with daptomycin oligomerising in the 
membrane creating a potassium efflux ultimately resulting in; membrane disruption; cessation of the 
synthesis of the macromolecules Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA) and protein 
synthesis; eventually leading to cell death. Unlike β-lactams this process is cell lysis independent with 
only the cell membrane, not the cell wall, disrupted [115]. Generally, daptomycin is well tolerated, 
although myopathy has been reported in some patients [116]. 
Figure 1. The structure of Daptomycin. Adapted from Steenbergen et al. 2005 [113]. 
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1.8.2. Polymyxins (B and E) 
Polymyxins are a group of cationic antimicrobials discovered in the late 1940s [117–119]. 
Polymyxin E was later identified in the 1950s [120]. Polymyxins are N-terminally fatty acylated 
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cationic lipopeptides consisting of a cyclic peptide structure attached to a hydrocarbon tail. Removal of 
the fatty acid tail reduces the antimicrobial activity of polymyxin [104]. They are isolated naturally 
from the Gram-positive bacteria Bacillus polymyxia [121]. Only two polymyxins are commercially 
available, polymyxin B and polymyxin E (colistin) [122]. Polymyxin B is a cyclic heptapeptide with a 
tripeptide side chain that is acylated at its amino terminus by a fatty acid. Polymyxin B consists of the 
amino acids D-phenylalanine, L-threonine and L-α-γ-diaminobutyric acid [123,124]. Colistin has the 
same structure as polymyxin B but D-phenylalanine is replaced by D-leucine [124]. A range of topical 
and parenteral formulations are available indicated for the treatment of Gram-negative skin and eye 
infections, including those involving Pseudomonas aeruginosa, with a powdered nebulizer solution 
available to treat multidrug resistant Gram-negative infection in cystic fibrosis patients [125–127]. The 
mechanism of action of the polmyxins is similar to cationic antimicrobial peptides in general [128,129]. 
Interaction of the hydrophobic tail with lipopolysaccharides present on the outer membrane of  
Gram-negative bacteria creates a detergent-like effect compromising the integrity of the bacterial 
membrane [130]. Polymyxins may also displace magnesium and calcium ions from cationic binding 
sites present at the bacterial cell surface resulting in leakage of cell contents from the cytoplasm [131]. 
The membrane permeabilisation effect also has the benefit of making Gram-negative bacteria more 
susceptible to hydrophobic antimicrobials for example erythromycin [132–134]. Polymyxins also have 
the benefit of binding to and neutralizing Gram-negative endotoxins [135,136]. However the systemic 
use of polymyxins is limited with nephrotoxicity, ototoxicity and neurotoxicity common [137–139]. 
Colistin methanesulphonate, a prodrug of colistin, has shown increased use therapeutically due 
possessing a lower toxicity profile than colistin itself [140]. 
2. Mechanism of Action of Antimicrobial Peptides  
2.1. Targeting of the Microbial Cell Membrane  
As with the majority of antimicrobials, interaction with the cell membrane of microorganisms  
is fundamental to the mode of action of cationic antimicrobial peptides. The significant difference  
in the compositions of eukaryotic membranes in comparison to prokaryotic membranes highlights  
the important selectivity of cationic antimicrobials for bacterial cells. Phospatidylcholine, 
phosphatidylethanolamine, an analogue of phospatidylcholine, sphingomyelin together with the 
sterols, ergosterol and cholesterol are predominantly found in eukaryotes and normally have no net 
charge leading to an overall neutrally charged phospholipid bilayer. In comparison prokaryotic 
bacterial cytoplasmic membranes are negatively charged, with a high electrical potential gradient, 
contributed in part to the presence of acidic hydroxylated phospholipids such as phosphatidylglycerol, 
cardiolipin and phosphatidylserine [12]. Cationic antimicrobial peptides will therefore bind preferentially 
to the negatively charged phospholipid bilayer of bacterial cells [34,141]. This is advantageous with 
regard to reducing toxicity in any potential therapeutic environment. The lack of specific receptors will 
also make it difficult for bacteria to develop resistance to the peptide. Bacteria would have to alter the 
properties of their membrane as a whole rather than specific receptors. The overall positive charge 
associated with cationic antimicrobial peptides means that initial electrostatic interaction with the 
bacterial cell membrane will involve areas of dense anionic charge. Acidic polymers such as teichoic 
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acids in Gram-positive [142] and phosphate groups present on lipopolysaccharides in Gram-negative 
bacteria [143] allow attachment of the peptide prior to formation of transmembrane pores and 
ultimately membrane permeabilization.  
Fungal cell membranes tend to share similar properties to the zwitterionic eukaryotic membranes [144]. 
Peptides that primarily possess antifungal activity tend to consist of neutral amino acids with regions 
of high polarity suggesting that a unique structure-activity relationship exists [145]. Proof of this 
structure activity relationship and the importance of lipophilic moieties in the peptide structure were 
provided by Lopez-Garcia et al. [146]. They demonstrated that there was a direct correlation between 
the antifungal activity of peptides and the ability of peptides to form aggregative complexes with lipid 
formulations. Four main hypotheses exist as to how antimicrobial peptides achieve entry into the 
bacterial cell (Figure 2: part A–D). These are the toroidal pore, aggregate, barrel stave, and  
carpet models.  
Figure 2. Proposed mechanisms of action of antimicrobial peptides. Antimicrobial 
peptides (cylinders) with the charged hydrophilic regions (red) and hydrophobic regions 
(blue). (A) The “aggregate” model: the antimicrobial peptides reorient to form an 
aggregate that spans the membrane, composed of peptide and lipid micelle complexes but 
with no particular orientation adopted; (B) The “toroidal pore” model occurs when the 
peptides insert perpendicular to the plane of the lipid bilayer, with hydrophilic groups on 
the peptide interacting with the membranous phospholipid head groups and the 
hydrophobic regions associating with the lipid core. A lipid bilayer lined pore is created as 
the membrane curves inwards; (C) The “barrel-stave” model also involves insertion of the 
peptides at a perpendicular orientation to the plane of the bilayer but staves are formed in a 
barrel shaped cluster due to hydrophilic portions of the peptide interacting with the lumen 
of the pore and hydrophobic regions of the peptide associating with the lipid bilayer;  
(D) The “carpet” model involves the aggregation of peptides at a parallel orientation to the 
lipid bilayer with localized carpeting of areas of the membrane. Micelles are formed above 
a critical threshold concentration leading to a detergent-like activity and the formation of 
pores in the membrane. Adapted from Jenssen, Hamill and Hancock 2006 [147]. 
A                           B                              C    D
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The toroidal pore model involves the peptide inserting perpendicular into the cell membrane via 
electrostatic interactions between the hydrophilic regions of the peptide and the phospholipid head of 
the bilayer. Hydrophobic regions of the peptide bend the lipid monolayers forming a central water core 
lined by lipid head groups and inserted peptides [148]. In doing this the membrane bends inwards such 
that the bilayer lines the channel as well as the peptides. A toroidal pore is thus formed by positive 
curvature, allowing entry of further antimicrobial peptide [149]. In the aggregate model a similar 
process occurs to that of the toroidal pore model. However, peptides do not adopt any specific 
orientation upon insertion into the membrane but cover the membrane as an aggregate of peptide and 
lipid micelles [150]. Channels that do form vary greatly, so much that partial membrane insertion may 
lead to the formation of negative curvature and peptide aggregation within the bilayer [151].  
Perpendicular insertion of the peptides forming barrel-like clusters or staves occurs in the barrel-stave 
model [152]. Pores can occur from as little as three peptide molecules and theoretically to allow  
these pores to form, peptides must have an amphipathic or hydrophobic α-helix, β-sheet structure or 
both [153]. Usually the barrel-stave model results in a transmembrane pore of unilateral size. Within 
this pore hydrophilic regions of the peptide oppose the lumen, forming the interior and Van der Waal’s 
attractions occurring between the hydrophobic peptide regions and the lipid core [154]. The carpet 
model suggests that peptides accumulate parallel to the membrane with the hydrophobic regions of the 
peptide associating with the anionic phospholipid head groups on the membrane surface and 
hydrophilic regions attracted to the polar solvent [155]. Localization of peptides occurs forming a 
carpet-like coating on the membrane until a threshold concentration is reached. At this threshold a 
detergent-like process occurs with the eventual formation of micelles and transient pores. Disruption of 
the membrane structure leads to membrane disintegration [156]. It has been hypothesized that the 
additional outer lipid membrane present on Gram-negative organisms consisting of lipopolysaccharides 
allows a self-promoted uptake pathway to occur for cationic peptides [157,158]. As the majority of these 
peptides have a high affinity for lipopolysaccharides they bind to them, competitively replacing 
divalent cations such as magnesium and calcium ions from their relative binding sites [159]. Both 
magnesium and calcium ions are required for cell surface stability via the cross-linking of carboxylated 
and phosphorylated head groups of lipids [160]. Removal of these divalent cations leads to distortion 
of the outer membrane forming holes through which further peptide and other small molecules (such as 
conventional antibiotics) can cross. The self-promoted uptake model provides an explanation as to why 
in Gram-negative bacteria many cationic antimicrobial peptides act in synergy with conventional 
antibiotics [161].  
Synergy of cationic antimicrobial peptides with standard antimicrobials is not limited to just  
Gram-negative bacteria but has been proven for both Gram-positive [162] and fungi also [163]. A 
similar pattern of membrane disruption has been demonstrated for antimicrobial peptides against a 
range of fungal pathogens. The rabbit α-defensin NP-2, magainin-2 and bovine lactoferrin have been 
shown to cause membrane permeabilization and cell wall damage in Candida albicans [164–166]. The 
antimicrobial lipopeptide iturin, obtained from cultures of Bacillus subtilis, is fungicidal through its 
activity on cell membranes [167]. Lipopeptide aggregates and lipopeptide/phospholipid complexes 
form at the peptide-membrane interface resulting in the creation of ionic pores that allows the 
increased influx of potassium ions and fungal cell death [168]. These pores may also provide a means 
by which ATP is released from damaged cells. Membrane damage results in leakage and localized 
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increases in extracellular ATP as the microbial membrane is damaged but intracellular metabolic 
processes continue. Vylkova et al. hypothesized that this may contribute to cell death in Candida 
albicans and other microorganisms by facilitating further peptide uptake or activating the host’s innate 
immune response with ATP acting as a chemo-attractant at the site of infection [169]. 
2.2. Mechanism of Action of Antimicrobial Peptides: Intracellular Targeting 
Membrane damage is only one of many mechanisms that antimicrobial peptides may possess in 
exerting microbial cell death. In many cases it may not be the principle mechanism. There is increasing 
evidence for intracellular targeting of microbes (Figure 3: part E–I) as both alternative and synergistic 
pathways to membrane rupture and cell lysis. The antimicrobial peptide buforin II, possessing a linear 
proline hinge and containing an amphipathic α-helical peptide, has been proven to translocate across 
the cell membrane without loss of the transmembrane potential and with intracellular contents intact 
even at five times the MIC. Cellular function of Escherichia coli is inhibited by accumulation of 
buforin II in the cytoplasm and via binding to DNA and RNA [170]. Binding to and inhibition of 
cellular nucleic acids by cationic antimicrobial peptides is feasible due to the polyanionic charges 
present in nucleic acids and also some intracellular enzymes [26,171].  
Some antimicrobial peptides such as indolicidin have been demonstrated to penetrate bacterial cell 
membranes rendering them relatively undamaged but with antibacterial activity achieved by inhibition 
of RNA, DNA and protein synthesis [172]. This contrasts to a mainly membrane active targeting of 
fungal cells by indolicidin via direct interactions with the phospholipid bilayer [173]. Other hypotheses 
for intracellular action include stimulation of the autolytic enzyme cascade [174]. Cationic antimicrobial 
peptides, for example lactoferrin and lysozyme, may mimic the action of β-lactam antibiotics and 
activate autolytic cell wall enzymes such as muramidases causing bacteriolysis [175]. Intracellular 
targeting of protein synthesis by degradation of proteins required for DNA replication has been shown 
to be a primary mechanism of action for indolicidin and the pig intestinal peptide PR-39 [176–178]. 
Indolicidin and lactoferricin B have also been shown to induce filamentation, a process in which 
bacterial cells continue to elongate but cannot divide as the septum does not develop, and significant 
cell lysis [179–181]. Filamentation results from inhibition of DNA synthesis [182].  
In mammals the antimicrobial cathelicidin peptides LL-37 and PR-39 have multiple membrane  
and intracellular mechanisms of action but they can also mitigate the immune response to foreign 
pathogens [183,184]. LL-37 induces the selective movement of neutrophils, monocytes and CD4  
T-lymphocyte cells allowing an increase in the adaptive and innate immune response [185,186]. The 
porcine peptide PR-39 promotes healing via stimulation of angiogenesis mediated by its degradation of 
hypoxia inducible factor 1a protein [187]. 
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Figure 3. The intracellular action of some antimicrobial peptides (E−I). (E) Dermaseptin, 
buforin-II and pleurocidin are antimicrobial peptides that have been shown to inhibit both 
DNA and RNA synthesis at MIC values [188]. Dermaseptin inhibits RNA synthesis in 
bacteria at MIC concentration or higher within 5 minutes, with lack of bactericidal action 
within 30 minutes in Escherichia coli evidence of a mainly intracellular action [189]. 
Buforin-II contains a single proline residue within its primary structure that allows 
translocation across cell membranes without membrane destruction, with binding to 
nucleic acids resulting in cell death [170,190]; (F) PR-39 and indolicidin have been shown 
to inhibit the rate of protein synthesis and is therefore a plausible target for antimicrobial 
peptides [13,180,191]; (G) Pyrrhocoricin and drosocin act one step later than the molecules 
of part E (dermaseptin, buforin-II and pleurocidin) and have been shown to reduce 
enzymatic activity via inhibition of ATPase activity of the heat-shock protein DnaK, an 
enzyme involved in chaperone-assisted protein folding [192–194]. Otvos and colleagues 
formed a chimeric dimer, with newly formed activity against Staphylococcus aureus and 
increased activity against previously sensitive Escherichia coli, by synthesizing a molecule 
that possessed pyrrhocoricin’s DnaK binding domain and drosocin’s high membrane 
permeating ability [195]; (H) Antimicrobial peptides may also inhibit resistance 
mechanisms linked to bacterial pathogenesis for example enzymes with anionic binding 
site pockets linked to the modification of aminoglycoside antibiotics [171]; (I) Lantibiotics 
such as mersacidin and nisin target the formation of structural components of the cell  
wall, specifically the transglycosylation of lipid II, necessary for the synthesis of 
peptidoglycan [196,197]. Adapted from Jenssen, Hamill and Hancock 2006 [147]. 
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Alternative bactericidal intracellular mechanisms are outlined in Figure 3: parts E-I. By possessing 
multiple microbial targets, antimicrobial peptides can be a therapeutically valuable tool as the potential 
for microbial resistance is low (perhaps negligible). The chances of resistance developing is lessened 
further by many antimicrobial peptides possessing similar MIC and minimum bactericidal 
concentration (MBC) values (MBC no more than double the value obtained for MIC), owing to mainly 
bactericidal action [198]. The intracellular mode of action of antimicrobial peptides against fungal 
pathogens is linked to interactions with the fungal mitochondrion, with targeting and perturbation of 
the mitochondrial membrane shown by Helmerhorst et al. [199]. The cationic peptides histatins, 
derived from the saliva of humans, bind to receptors present on the fungal cell membrane and when 
present in the cytoplasm they target fungal mitochondria [200]. The echinocandins are an antimicrobial 
peptide family sourced from Aspergillus nidulans that includes the peptides anidulafungin caspofungin, 
and micafungin [201]. They have been shown to inhibit β-(1,3)-glucan synthase, an enzyme responsible 
for the production of the essential fungal cell wall component β-(1,3)-glucan [202–204]. 
3. Development of Resistance to Antimicrobial Peptides 
The multiple modes of action utilized by antimicrobial peptides reduces the ability of 
microorganisms to develop resistance, with cidal activity also shown against bacteria resistant to 
standard antibiotics [205]. The formation of a highly hydrated extracellular polymeric phenotype or 
biofilm contributes to antimicrobial resistance by blocking the transport of antimicrobials through the 
biofilm matrix. Possible mechanisms for this to occur are by binding of the biofilm to them directly, as 
in the case of positively charged aminoglycoside antibiotics, restricting their permeation and by 
restricting diffusion of larger antimicrobials [206,207]. 
Extracellular DNA may also play a role in increased resistance of biofilm forms of Pseudomonas 
aeruginosa against cationic antimicrobial peptides. Extracellular DNA is a cation chelator and acts to 
sequester cations from the surrounding environment and also plays a role in the modification of the 
cationic antimicrobial peptide binding site lipid A by the sugar dehydrogenases enzyme Undecaprenyl 
phosphate-glucose dehydrogenase and covalent binding to 4-amino-4-deoxy-L-arabinose [208]. 
Resistance is conferred via covalent modification of the cationic antimicrobial binding site lipid A. 
Lipid A is a hydrophobic anchor situated on the outer surface of the inner membrane of Gram-negative 
bacteria and acts as an anionic membrane target for cationic drugs such as polymyxin and also  
cationic antimicrobial peptides. Covalent binding to 4-amino-4-deoxy-L-arabinose moiety reduces 
both the anionic charge of lipid A and its affinity for cationic antimicrobials. In Gram-negative bacteria 
such as Escherichia coli the expression of genes (arn and ugd operons) involved in Undecaprenyl 
phosphate-4-amino-4-deoxy-L-arabinose production are controlled by the two component quorum 
sensing systems PhoP/PhoQ and PmrA/PmrB; and/or the RcsA/RcsB/RcsC system as outlined in  
Figures 4, 5 and 6.  
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Figure 4. The synthesis of Undecaprenyl phosphate-glucuronic acid via quorum sensing 
systems. The two component quorum sensing systems PhoP/PhoQ and PmrA/PmrB; or the 
RcsA/RcsB/RcsC system alone allow the expression of genes (ugd) involved in the 
intracellular synthesis of the 4-amino-4-deoxy-L-arabinose precursor: Undecaprenyl 
phosphate-glucuronic acid. Both scenarios involve the phosphorylation of the protein Ugd 
by the membrane bound autophosphorylated protein-tyrosine kinase Wzc and/or Etk. Etk 
and Wzc are a BY-kinase (a newly defined group of enzymes involved in protein-tyrosine 
phosphorylation) of Escherichia coli and are involved in the production of the group IV 
capsule surrounding the cell membrane [209]. The wca operon is upregulated by the 
RcsA/RcsB/RcsC system and consists of 19 genes with the third gene in order of 
transcription being the wzc gene that has been shown to encode a membrane bound 
autophosphorylated protein-tyrosine kinase Wzc [210]. Etk is coded for by the etk gene 
present on the ymc operon of some pathogenic strains of Escherichia coli [211]. The 
mechanism of the ymc operon is itself unknown, although it could possibly be a promoter 
of etk expression. Key: UDP: Undecaprenyl phosphate. (Adapted from Lacour, 2008 [212]) 
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Figure 5. The synthesis of Undecaprenyl Phosphate-α-4-amino-4-deoxy-L-arabinose  
from Undecaprenyl-Glucuronic acid. The enzymes ArnA, ArnB, ArnC and ArnT are 
produced by transcription of the arn operon which is upregulated by the  
RcsA/RcsB/RcsC and PmrA/PmrB quorum sensing systems. The enzyme ArnA catalyses 
the oxidative decarboxylation of Undecaprenyl -glucuronic acid, thus forming an 
Undecaprenyl -4-keto-pyranose intermediate. ArnC catalyzes the transfer of the  
4-amino-4-deoxy-L-arabinose moiety to Undecaprenyl phosphate in the inner membrane, 
forming the Undecaprenyl phosphate-α-4-amino-4-deoxy-L-arabinose. Key: UDP: 
Undecaprenyl phosphate. (Adapted from Lacour,S. 2008 [212]). 
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Figure 6. The transfer of 4-amino-4-deoxy-L-arabinose moiety to Lipid A.  
Translocation to the outer surface of the inner membrane occurs via an unknown 
mechanism. ArnT transfer the 4-amino-4-deoxy-L-arabinose moiety from Undecaprenyl  
phosphate-α-4-amino-4-deoxy-L-arabinose to Lipid A, thereby reducing the affinity of 
Lipid A for polymyxin and other cationic antimicrobial peptides. (Adapted from Lacour, S. 
2008 [212]). 
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4. Future Perspectives 
As biocides antimicrobial peptides have the potential to eradicate the most resistant forms of 
clinically relevant biofilm forming pathogens. Lipopeptides such as polymyxin B and daptomycin are 
already utilized in topical formulations [213], therefore the potential exists for the ornithine and 
tryptophan containing peptides to be exploited similarly. More advanced forms of topical treatment 
would mimic the use of the polycationic lipopeptide colistin and the polycationic trisaccharides 
tobramycin and gentamicin as aerosol therapy for the treatment of persistent lung infections in cystic 
fibrosis patients [214,215]. The potential for natural and synthetic peptides as therapeutic molecules go 
beyond the boundaries of microbial biofilm infection. Research has extended to the use of these 
peptides from areas as diverse as cancer treatment [216], to the eradication of sexually transmitted 
diseases [217], such as HIV [218], with a dual role as an effective contraceptive spermicide [219,220]. 
A group of cationic peptides, referred to as cell-penetrating peptides can translocate into the cell 
cytoplasm without disruption of the cell membrane. Peptides such as Apidaecins have the potential to 
act as precursors for the transport of alternative drugs to mammalian cells [221]. Despite the fact there 
are thousands of naturally sourced antimicrobial peptides and millions of potential synthetic 
possibilities there have been limited clinical trials based on antimicrobial peptides [222]. Only a 
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relative few, for example daptomycin, have entered into clinical trials and therapeutic use based on 
in vitro results and animal studies [106,223,224]. Issues still remain with regard to the stability of 
peptide based formulations in vivo and the large scale production costs of these peptides. It is expected 
that future research will allow the area of antimicrobial peptides to be harnessed therapeutically with 
the same degree of evolutionary success as they are utilized in nature as components of innate 
immunity. Antimicrobial peptides fulfill a number of the criteria expected from an ‘ideal’ biocide, 
namely performance (high cidal activity and a rapid rate of kill across a range of microorganisms), 
environmental fate (facile bioremediation), safety and cost. 
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